Valuation
- Market cap
- 0
- Revenue TTM
- $0
- Net income TTM
- $-34,806,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 62,600
- Avg volume
- —
- Day's range
- $13.31 – $14.10
- Shares out
- —
- Stochastic %K
- 59%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- $29.25
Company profile
TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize therapeutic targets, using computational mapping, which uses in silico tools and a human tissue bank...
Show more
TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize therapeutic targets, using computational mapping, which uses in silico tools and a human tissue bank and atlas of human treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue states in tregs and reprograms blood-derived Tregs to recreate human tissue-specific pathways in vitro for target validation; and the Phenotypic Assay Cascade, a suite of high-throughput functional fingerprinting assays that test targets across donors and inflammatory contexts. The company develops TRB-061 an investigational tumor necrosis factor receptor 2 (TNFR2) agonist and fragment crystallizable-fusion (Fc-fusion) protein designed to selectively agonize TNFR2 to activate and expand Tregs in inflamed tissues. The company also develops TRB-071, an agonist designed to augment tissue Tregs and block an inflammatory signaling pathway, for inflammatory bowel disease. Additionally, it advances TRB-051, a partnered modulator of immune effector cells, for autoimmune and inflammatory diseases including lupus with cutaneous involvement. The company also advances preclinical-stage programs addressing tissue Treg biology informed by the Deep Biology Platform. TRex Bio, Inc. was incorporated in 2018 and is based in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (650) 567-5582
- Website
- https://trex.bio
- Address
- 269 East Grand Avenue, Suite 300, South San Francisco, United States
Latest news
No headlines yet.